



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Azomyr

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion / Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
WS/2804/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in	13/02/2025		SmPC and PL	The SmPC section 3 Pharmaceutical form has been updated as follows: instead of embossed film-cotted tablets with elongated letters "S" and "P" it now mentions "C5". The Package Leaflet have been updated accordingly to reflect the change.

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	imprints, bossing or other markings B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)				
WS/2757/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter wit its corresponding test method as a result of a safety or quality issue B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	03/10/2024	n/a		

WS/2654	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	20/06/2024		SmPC and PL	
WS/2464	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.7.a - Deletion of - a pharmaceutical form	08/06/2023	09/10/2023	SmPC, Annex II, Labelling and PL	
IG/1573	A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release	14/12/2022	09/10/2023	Annex II and PL	
WS/2314	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.a.2.z - Change in the shape or dimensions of the pharmaceutical form - Other variation	22/09/2022	09/10/2023	SmPC and PL	
PSUSA/962/202107	Periodic Safety Update EU Single assessment - desloratadine	24/03/2022	30/05/2022	SmPC and PL	Please refer to Aeri-us-Azomyr-Neoclarityn-Desloratadine Teva-Dassel-ta-Desloratadine Actavis-Desloratadine ratiopharm-EMEA/H/C/PSUSA/00000962/202107 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
IG/1487	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change	28/02/2022	n/a		

	in the manufacturing process				
IB/0104	To update section 3 of the SmPC with the description of the pharmaceutical form film-coated tablets in line with currently registered Module 3.2.P.1. The PL is updated accordingly. The MAH took the opportunity to update the Package Leaflet with revised contact details of local representative for Bulgaria, Germany, Hungary, Lithuania, and the Netherlands. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	17/01/2022	30/05/2022	SmPC and PL	
IG/1427	B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products	12/08/2021	n/a		
WS/2057	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of an updated RMP version 2.1 in order to align with GVP Module V (rev 2) template which includes updates to the list of safety concerns and reflects the completion of a post-authorisation safety study listed as category 3 (A Nordic register-based study which studied the association between the use of desloratadine and risk of seizures, supraventricular tachycardia, and atrial fibrillation or flutter: EUPAS15038) assessed in EMEA/H/WS1655.	10/06/2021	n/a		In line with the new definitions as set in the Revision 2 of the guideline on Good Pharmacovigilance Practice (GVP) Module V on Risk Management Plans (RMP), the removal of all the safety concerns in the RMP was acceptable to the PRAC. Other changes have been brought in other sections of the RMP, in order to update some data with more recent information, especially to reflect the completion of the post-authorisation safety study (EUPAS15038).

	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
T/0101	Transfer of Marketing Authorisation	17/03/2021	10/05/2021	SmPC, Labelling and PL	
WS/1834	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	28/01/2021	10/05/2021	SmPC, Annex II, Labelling and PL	
N/0100	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/01/2021	10/05/2021	PL	
N/0099	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	11/12/2020	21/04/2021	PL	
N/0097	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	10/02/2020	21/04/2021	PL	
WS/1655	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	16/01/2020	21/04/2021	SmPC	The objective of the retrospective observational post-authorisation safety study (PASS) using person-specific linkage of data from the national population registers from Denmark, Finland, and Sweden was to assess the potential

	C.I.13: Update of section 4.8 of the SmPC to reflect an increased incidence of new-onset seizure in patients 0 to 19 years when receiving desloratadine compared with periods not receiving desloratadine based on the results of the final report from study (EUPAS15038) listed as a category 3 study in the RMP. This is a non-interventional non-imposed PASS study designed to assess the potential risk of desloratadine exposure on seizures, supraventricular tachycardia, and atrial fibrillation or flutter. In addition, section 4.2 of the SmPC is updated to remove that "no data are available" in the paediatric population and section 4.4 is updated to include a cross reference to section 4.8 of the SmPC. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority				risk of desloratadine (DL) exposure on seizures, supraventricular tachycardia (SVT), and atrial fibrillation or flutter (A-fib/flu). The PASS indicated an increased incidence of new-onset seizure in patients 0 to 19 years of age when receiving desloratadine compared with periods not receiving desloratadine. Among children 0-4 years old, the adjusted absolute increase was 37.5 (95% Confidence Interval (CI) 10.5-64.5) per 100,000 person years (PY) with a background rate of new onset seizure of 80.3 per 100,000 PY. Among patients 5-19 years of age, the adjusted absolute increase was 11.3 (95% CI 2.3-20.2) per 100,000 PY with a background rate of 36.4 per 100,000 PY. The product information already includes a special warning and precaution for use on seizures, in addition, it is listed as an adverse reaction with a frequency very rare. Nonetheless, based on the results of this study, the section 4.8 of the SmPC is updated to reflect the increased incidence of new-onset seizure in patients 0 to 19 years of age receiving DL compared with periods not receiving desloratadine. The section 4.2 is also updated to remove the sentence that "no data are available" in the paediatric population and the section 4.4 is updated to include a cross reference to section 4.8 of the SmPC. The study found no association between current use of DL and risk of first SVT. The study also found an association between current use of DL and risk of first A-fib/flu that persisted after adjustment for preselected confounders (aIRR 1.06, 95% CI 1.01; 1.12). In age-stratified analyses, the association was strongest for patients aged ≥ 65 years (aIRR 1.08, 95% CI 1.02; 1.15). In view of the results of this PASS, further information is required regarding the risk of A-fib/flu in
--	--	--	--	--	---

					special patient groups and seizure. This will be addressed in the next PSUR by the MAH in 2021.
IG/1146	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	04/10/2019	n/a		
T/0094	Transfer of Marketing Authorisation	23/05/2018	29/06/2018	SmPC, Labelling and PL	
IG/0925	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	13/04/2018	n/a		
IG/0875	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	08/12/2017	29/06/2018	SmPC and PL	
N/0091	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	19/10/2017	29/06/2018	Labelling	
PSUSA/962/201607	Periodic Safety Update EU Single assessment - desloratadine	23/03/2017	24/05/2017	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/962/201607.
IG/0775	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	27/01/2017	n/a		
IG/0704	B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the	01/08/2016	n/a		

	relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)				
WS/0928	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	19/05/2016	n/a		
N/0087	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	03/05/2016	24/05/2017	PL	
IG/0673	A.7 - Administrative change - Deletion of manufacturing sites	06/04/2016	n/a		
IG/0619	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	30/09/2015	n/a		
WS/0641	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 5.2 of the SmPC to include further information regarding renally impaired patients. Moreover, a new RMP (version 1.1) was submitted in line with the request of the EMA as a result of the assessment of the 9th PSUR	26/03/2015	06/08/2015	SmPC and Annex II	The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single-dose study and one multiple dose study). In the single-dose study, the exposure to desloratadine was approximately 2 and 2.5-fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple-dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine

	(PSU 048) for Acrius, Azomyr and Neoclarityn. In addition, the MAH took the opportunity to update Annex II in line with the latest QRD template (version 9) regarding standard text for RMP requirements. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				was ~1.5-fold greater in subjects with mild to moderate CRI and ~2.5- fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and Cmax) of desloratadine and 3-hydroxydesloratadine were not clinically relevant.
WS/0590	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of SmPC sections 4.5, 4.6, 4.8 and 4.9 with new safety information, upon request by the CHMP following the assessment of PS2 049.3 (follow up to PSUR 10). The Package Leaflet has been updated accordingly. In addition, the MAH has aligned the SmPC and Package Leaflet with the latest QRD template, revision 9 and made some minor editorial changes in the SmPC. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH	26/02/2015	06/08/2015	SmPC and PL	New information: Paediatric population: - In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated with desloratadine and 6.9 % of patients receiving placebo. - Other undesirable effects reported during the post marketing period in paediatric patients with an unknown frequency included QT prolongation, arrhythmia, and bradycardia. - The adverse event profile associated with overdosage, as seen during post marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher. - Interaction studies have only been performed in adults. Adult population: - A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor feto/ neonatal toxicity of desloratadine.

					- Cases of alcohol intolerance and intoxication have been reported during post marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.
IG/0534	A.7 - Administrative change - Deletion of manufacturing sites	24/02/2015	n/a		
IG/0483	A.7 - Administrative change - Deletion of manufacturing sites	13/02/2015	n/a		
IG/0491	B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier	27/10/2014	n/a		
WS/0587	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.7.a - Deletion of - a pharmaceutical form	25/09/2014	06/08/2015	SmPC, Annex II, Labelling and PL	
IB/0076	B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	29/08/2014	06/08/2015	SmPC and PL	
IG/0451	B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS	01/08/2014	n/a		
WS/0576	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	24/07/2014	n/a		

	This was an application following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Completion of information on the container closure system following a CHMP recommendation. B.II.e.z - Change in container closure system of the Finished Product - Other variation				
IG/0444	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	01/07/2014	n/a		
II/0071	Update of section 4.8 of the SmPC to include photosensitivity as an adverse event as requested by the CHMP following the assessment of the PSUR 10. Section 4 of the Package Leaflet was updated accordingly. In addition, the MAH took the opportunity to update the Portuguese local representative contact in the Package Leaflet. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation	26/06/2014	19/08/2014	SmPC and PL	Following the assessment of the PSUR 10 (covering the period from 16 July 2009 to 15 July 2011), the risk of photosensitivity was reviewed in detail, with a cumulative analysis of the case reports performed and discussed. Based on the data available, the CHMP agreed that, although the reporting rate for photosensitivity was very low, patients should be informed about this potential adverse event. 'Photosensitivity' with an unknown frequency was added to the Product Information. The addition of this adverse event does not adversely affect the benefit/risk balance of Azomyr.
N/0073	Update of the local representative's contact details for Portugal in the package leaflet. Minor change in labelling or package leaflet not	14/02/2014	19/08/2014	PL	

	connected with the SPC (Art. 61.3 Notification)				
IG/0366	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	08/11/2013	n/a		
IB/0068	Update of the Product Information to QRD template 9.0 and inclusion of an additional local representative of the MAH for Croatia. The MAH also took the opportunity to make editorial changes to the English annexes. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	13/09/2013	19/08/2014	SmPC, Annex II, Labelling and PL	
IB/0067	B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation	26/06/2013	n/a		
IG/0291/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites	06/06/2013	n/a		

N/0065	"Update of the local representatives contact details for Greece, Italy, Portugal and Poland in the package leaflet." Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	04/02/2013	19/08/2014	PL	
IG/0249	B.III.2.a.2 - Change of specification(s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material	07/12/2012	n/a		
N/0062	Update of the local representatives contact details in the package leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	05/09/2012	19/08/2014	PL	
IG/0184	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	21/08/2012	n/a		
IG/0195	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	28/06/2012	n/a		
II/0059	Change in the active substance synthesis B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product	21/06/2012	21/06/2012		

IG/0188	B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place	11/06/2012	n/a		
IB/0057/G	This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place	13/04/2012	n/a		
IG/0117/G	This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV	18/11/2011	09/02/2012	Annex II	

	C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system				
T/0053	Transfer of MA from SP Europe to Merck Sharp & Dohme Ltd. Transfer of Marketing Authorisation	12/08/2011	16/09/2011	SmPC, Labelling and PL	
N/0052	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	04/04/2011	n/a	PL	
IG/0054	B.III.1.a.1 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	11/03/2011	n/a		
IG/0053	A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS	24/02/2011	n/a		
N/0051	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	21/01/2011	n/a	PL	
N/0050	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	20/10/2010	n/a	PL	
II/0047	Update of the Detailed Description of the Pharmacovigilance System (DDPS) including change of the Qualified Person for Pharmacovigilance	21/01/2010	23/03/2010	Annex II	The DDPS has been updated (version 7, December 2009) to reflect the change of the QPPV as well as to notify other changes to the DDPS performed since the last approved

	(QPPV). Consequently, Annex II has been updated with the new version number. Update of DDPS (Pharmacovigilance)				version. Consequently, Annex II has been updated including the new version number of the agreed DDPS. The CHMP considers that the Pharmacovigilance System as described by the MAH is acceptable.
IA/0049	IA_29_b_Change in qual./quant. composition of immediate packaging - all other pharm. forms	18/12/2009	n/a		
IA/0048	IA_09_Deletion of manufacturing site IA_47_a_Deletion of a pharmaceutical form	05/11/2009	n/a	SmPC, Annex II, Labelling and PL	
IB/0046	IB_33_Minor change in the manufacture of the finished product	14/07/2009	n/a		
N/0045	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/03/2009	n/a	PL	
N/0043	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	08/12/2008	n/a	PL	
IA/0044	IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site	24/10/2008	n/a		
II/0039	Extension of indication for Azomyr from 'chronic idiopathic urticaria' to 'urticaria'. Extension of Indication	21/02/2008	31/03/2008	SmPC and PL	The CHMP variation assessment report will be published as part of the EPAR, following review/deletion of confidential information.
IA/0042	IA_05_Change in the name and/or address of a manufacturer of the finished product	30/01/2008	n/a		

IB/0040	IB_10_Minor change in the manufacturing process of the active substance	09/01/2008	n/a		
IA/0041	IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold	18/12/2007	n/a		
N/0038	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/10/2007	n/a	PL	
N/0036	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/08/2007	n/a	PL	
IB/0037	IB_20_c_Change in test procedure for an excipient - other changes	27/07/2007	n/a		
II/0035	Update of sections 4.2 and 5.1 of the Summary of Product Characteristics (SPC) for all pharmaceutical forms; section 4.8 of the SPC for Azomyr film-coated tablet, orodispersible tablet and oral lyophilisate presentations, further to the CHMP conclusions on provision of further data related to the paediatric population. Section 4 of the Package Leaflet (PL) has been amended accordingly. Update of the Production Information to include changes already approved for Azomyr orodispersible tablet and oral solution presentations and to be in accordance with the latest QRD templates. Editorial correction was made to section 7 of the SPC. Update of the list of the local representatives in the PL.	26/04/2007	05/06/2007	SmPC and PL	Based on the provision of further data related to the paediatric population, the CHMP recommended an update of sections 4.2 and 5.1 of the Summary of Product Characteristics (SPC) for all pharmaceutical forms and section 4.8 of the SPC for Azomyr film-coated tablet, orodispersible tablet and oral lyophilisate presentations. The CHMP also recommended to amend section 4 of the Package Leaflet (PL) accordingly. In line with the CHMP's recommendation, the MAH included into the relevant sections of the SPC/PL the following information: - there is limited clinical trial efficacy experience with the use of desloratadine in children aged 12-17 years; - efficacy of Azomyr syrup has not been investigated in paediatric trials in children less than 12 years of age; - the efficacy of Azomyr tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age;

	Update of Summary of Product Characteristics and Package Leaflet				- in adolescents, headache was the most commonly reported side effect. Additionally, changes were made to align the Product Information for all pharmaceutical forms.
X/0033	The MAH submitted an extension application for a new reformulated syrup. The proposed formulation is mainly intended for paediatric use. It is a suitable formulation for the recommended patient age and the likely duration of the treatment, since it is sugar-free, preservative and colorant-free. The MAH will discontinue, for the EU Member States, distribution to local representatives of the desloratadine current syrup formulation within an agreed timeframe. Annex I_2.(d) Change or addition of a new pharmaceutical form	22/02/2007	23/04/2007	SmPC, Labelling and PL	
X/0032	The MAH submitted an extension application for a new reformulated syrup. The proposed formulation is mainly intended for paediatric use. It is a suitable formulation for the recommended patient age and the likely duration of the treatment, since it is sugar-free, preservative and colorant-free. The MAH will discontinue, for the EU Member States, distribution to local representatives of the desloratadine current syrup formulation within an agreed timeframe. Annex I_2.(d) Change or addition of a new pharmaceutical form	22/02/2007	23/04/2007	SmPC, Labelling and PL	The MAH submitted an extension application to add a new pharmaceutical form ie orodispersible tablets. The orodispersible tablets may be used in adults and children aged 12 years and over (5mg dose) and in children aged 6 to 11 years old (2.5 mg dose) in the currently approved indications. The overall benefit/risk assessment for the orodispersible tablets was considered positive. The bioequivalence between the already marketed film-coated tablets and the orodispersible formulations has been established.

N/0034	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	08/02/2007	n/a	PL	
II/0031	This variation refers to an update of sections 4.2 and 5.1 of the Summary Product Characteristics (SPC) to include the terms 'intermittent' and 'persistent' allergic rhinitis according to the Allergic Rhinitis and its impact on asthma (ARIA) guidelines. Cross references of section 5.1 in both sections 4.1 and 4.2 of the SPC were also made. Section 3 of the Package Leaflet (PL) was amended accordingly. Update of Summary of Product Characteristics and Package Leaflet	27/07/2006	01/09/2006	SmPC and PL	According to the Allergic Rhinitis and its impact on asthma (ARIA) guidelines, intermittent allergic rhinitis means that the symptoms are present for less than 4 days per week or less than 4 weeks and persistent allergic rhinitis means that symptoms are present for at least 4 days per week and for more than 4 weeks. Based on data provided by the MAH on the classification of Allergic Rhinitis and according to the ARIA guidelines, the CHMP concluded that the information on intermittent and persistent allergic rhinitis could be reflected in sections 4.2 and 5.1 of the SPC. Cross-reference of section 5.1 in both sections 4.1 and 4.2 of the SPC were also made and Section 3 of the Package Leaflet (PL) was amended accordingly. The CHMP considered these changes to be acceptable.
R/0028	Renewal of the marketing authorisation.	14/12/2005	09/02/2006	SmPC, Annex II, Labelling and PL	
II/0030	Update of or change(s) to the pharmaceutical documentation	14/12/2005	20/01/2006	Annex II and PL	
II/0027	The Marketing Authorisation Holder applied for an update of section 4.8 of the Summary of Product Characteristics to include 'psychomotor hyperactivity' and 'seizures' further to the adoption of the CHMP conclusions on the sixth periodic safety update report on 26 May 2005. Section 4 of the Package Leaflet has been amended accordingly.	17/11/2005	09/01/2006	SmPC and PL	In the sixth PSUR, a cumulative review of cases of extrapyramidal disorders identified 34 cases, including psychomotor hyperactivity (13), hyperkinesia (6), abnormal coordination (6), ataxia (4), hypokinesia (1), tremor (2), tic (1), gait disturbance (1), dyskinesia (1) and extrapyramidal disorder (2). Positive dechallenge was observed in 14 cases (ataxia: 3, hyperkinesia: 3, abnormal coordination: 3, extrapyramidal symptoms: 1, psychomotor

	Update of Summary of Product Characteristics and Package Leaflet				activity: 4) with positive rechallenge in 2 of the cases (ataxia, abnormal coordination). In the sixth PSUR, three new cases of seizures were reported in addition to the review of cases of seizures performed in the previous PSUR and which identified 18 cases (7 possibly related to the use of desloratadine). Further to the assessment of PSUR 6, the CHMP concluded that an update of the SPC was necessary in order to reflect this information. Therefore, the MAH submitted a type II variation to update the SPC and provided further data. Based on these data, the CHMP concluded that the majority of reported extrapyramidal symptoms were psychomotor hyperactivity. The CHMP therefore recommended including 'psychomotor hyperactivity' to section 4.8 of the SPC. In addition, the CHMP considered acceptable the inclusion of the term 'seizures' to section 4.8 of the SPC. Section 4 of the PL has been amended accordingly.
N/0029	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/11/2005	n/a	PL	
N/0026	The Marketing Authorisation Holder applied for an update of section 4.8 of the Summary of Product Characteristics to include 'psychomotor hyperactivity' and 'seizures' further to the adoption of the CHMP conclusions on the sixth periodic safety update report on 26 May 2005. Section 4 of the Package Leaflet has been amended accordingly. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/09/2005	n/a	PL	In the sixth PSUR, a cumulative review of cases of extrapyramidal disorders identified 34 cases, including psychomotor hyperactivity (13), hyperkinesia (6), abnormal coordination (6), ataxia (4), hypokinesia (1), tremor (2), tic (1), gait disturbance (1), dyskinesia (1) and extrapyramidal disorder (2). Positive dechallenge was observed in 14 cases (ataxia: 3, hyperkinesia: 3, abnormal coordination: 3, extrapyramidal symptoms: 1, psychomotor activity: 4) with positive rechallenge in 2 of the cases (ataxia, abnormal coordination). In the sixth PSUR, three

					new cases of seizures were reported in addition to the review of cases of seizures performed in the previous PSUR and which identified 18 cases (7 possibly related to the use of desloratadine). Further to the assessment of PSUR 6, the CHMP concluded that an update of the SPC was necessary in order to reflect this information. Therefore, the MAH submitted a type II variation to update the SPC and provided further data. Based on these data, the CHMP concluded that the majority of reported extrapyramidal symptoms were psychomotor hyperactivity. The CHMP therefore recommended including 'psychomotor hyperactivity' to section 4.8 of the SPC. In addition, the CHMP considered acceptable the inclusion of the term 'seizures' to section 4.8 of the SPC. Section 4 of the PL has been amended accordingly.
N/0025	The Marketing Authorisation Holder (MAH) applied for an update of the details of the Polish and Spanish (film-coated tablet and syrup presentations only) local representatives and for a correction of the postal codes of several local representatives in the Package Leaflet. In addition the MAH applied for the inclusion of minor linguistic corrections to the Swedish, Dutch, French, Finnish, Norwegian and Italian version of the Labelling and Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	25/07/2005	n/a	Labelling and PL	
II/0024	This Type II Variation was submitted further to the adoption of the CHMP conclusions on the Benefit-Risk	18/11/2004	10/01/2005	SmPC, Labelling and	The MAH had been requested to submit a review of the events myalgia, insomnia and dyspnoea, which was

	assessment, to the CHMP conclusions on the fifth PSUR and to the CHMP conclusions on the Supplemental Safety Report for the desloratadine containing products. The adverse events "myalgia", "insomnia", dyspnoea" and hepatitis" were added to section 4.8 of the SPC and reflected in the Package Leaflet. The MAH also took the opportunity to combine the labelling, to change the word "container" to "package" in the SPC, labelling and Package Leaflet of the syrup and to update the information on the local representatives. Update of Summary of Product Characteristics, Labelling and Package Leaflet			PL	submitted with the fifth PSUR. The MAH had also been requested to monitor hepatic reactions. The MAH had received fifty-one cases of myalgia and other related muscle disorders (cramps, twitching, weakness, spasms and stiffness). Of the 53 events of insomnia, 21 cases may have resulted from desloratadine intake (positive rechallenge, de-challenge). Although this is a very low number in comparison to the market experience, the reporting rate of insomnia is probably also very low. The review of dyspnoea (incl: bronchospasm and asthma) included 91 cases (100 ADRs). Of these 63 were dyspnoea. Dyspnoea may be associated with hypersensitivity reactions and should therefore be mentioned among the symptoms of hypersensitivity in the SPC. The MAH therefore applied to include the terms "myalgia", "insomnia", and "dyspnoea" in section 4.8 of the SPC. One case of well-documented hepatitis with hepatic necrosis was identified. A further 19 cases of cholestasis, jaundice, hepatocellular damage and hepatitis were found, 12 of which contained the specific term "hepatitis". Although "Elevation of liver enzymes" and "increased bilirubin" are listed in the SPC, these were not considered to fully cover the possible occurrence of hepatitis. The MAH therefore applied for inclusion of the term "hepatitis" in section 4.8 of the SPC.
II/0022	A change to extend the dosing range of the Azomyr syrup to include children between the age of 1 and 2 years.	29/07/2004	20/09/2004	SmPC and PL	Efficacy and safety in the patient population between 1 and 2 years was supported by an extrapolation of evidence from adequate and controlled studies of desloratadine in adults and in children between 2 and 12 years of age. The

	Update of Summary of Product Characteristics and Package Leaflet				MAH also submitted the results of a single-dose pharmacokinetic study (P01341) that enrolled 58 paediatric volunteers with allergic disorders age 6 months to <2 years and from a 15-day randomised, double-blind, placebo-controlled, parallel-group safety study (P01368) in 255 children age =6 months to <2 years. The CHMP concluded that in daily practise it is particularly difficult to make the diagnosis of AR in the age group of 1 to 2 years due to the fact that there are no specific pathognomonic symptoms distinguishing between infectious and allergic rhinitis and the fact that in this age group infectious rhinitis is extremely frequent. However, the CHMP consider it acceptable to extend the use of desloratadine below the age of 2 years down to 1 year for treating AR and CIU as the MAH fulfilled the EU requirements for the extension of the medicinal product, adequate pharmaco-kinetic studies have been performed showing that the product is safe and does not behave different in children down to 1 year of age. Furthermore adequate information has been added to the SPC (section 4.2, 4.4, 4.8, 5.1, and 5.2) informing the prescriber of the difficulty in distinguishing AR from other forms of rhinitis in the age group below 2 years and of the lack of data to support the treatment of infectious rhinitis. The corresponding sections of the Package Leaflet (section 2, 3, and 4) have been updated correspondingly.
N/0023	The Marketing Authorisation Holder applied for the inclusion of additional local representatives of the Marketing Authorisation Holder for all new Member	13/05/2004	n/a	PL	

	States. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)				
II/0021	Update of Summary of Product Characteristics and Package Leaflet	20/11/2003	12/02/2004	SmPC and PL	
II/0020	Update of Summary of Product Characteristics and Package Leaflet	25/04/2003	30/07/2003	SmPC and PL	
II/0019	Update of Summary of Product Characteristics and Package Leaflet	25/04/2003	30/07/2003	SmPC and PL	
I/0018	15_Minor changes in manufacture of the medicinal product	17/03/2003	26/03/2003		
I/0017	01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process	17/03/2003	26/03/2003		
II/0016	Update of Summary of Product Characteristics and Package Leaflet	18/12/2002	17/03/2003	SmPC and PL	
II/0011	Update of Summary of Product Characteristics	27/06/2002	30/09/2002	SmPC	
II/0010	Extension of Indication	27/06/2002	30/09/2002	SmPC and PL	
I/0013	01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process	07/08/2002	30/09/2002	Annex II and PL	
I/0014	15_Minor changes in manufacture of the medicinal product	07/08/2002	30/08/2002		

	17_Change in specification of the medicinal product 25_Change in test procedures of the medicinal product				
I/0012	01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process	07/08/2002	30/08/2002		
II/0009	Update of Summary of Product Characteristics and Package Leaflet	25/04/2002	18/07/2002	SmPC and PL	
II/0006	Extension of Indication	21/02/2002	17/05/2002	SmPC and PL	
X/0005	X-3-iv_Change or addition of a new pharmaceutical form	13/12/2001	16/04/2002	SmPC, Annex II, Labelling and PL	
X/0004	X-3-iv_Change or addition of a new pharmaceutical form	13/12/2001	16/04/2002	SmPC, Annex II, Labelling and PL	
II/0007	Update of Summary of Product Characteristics	13/12/2001	12/04/2002	SmPC	
I/0008	03_Change in the name and/or address of the marketing authorisation holder	26/02/2002	13/03/2002		
II/0002	Update of the Summary of Product Characteristics following the availability of new interaction information Update of Summary of Product Characteristics	31/05/2001	20/09/2001	SmPC	Study P01380 evaluated the effect of grapefruit juice on desloratadine and fexofenadine (FX) pharmacokinetics. 19 of the 24 subjects were Hispanic (from the Miami area). The bioavailability of DL, measured in terms of plasma DL and 3-OH DL levels, was unaltered, while FX C _{max} and AUC were reduced by ~ 30 % in the presence of grapefruit juice. The effects of grapefruit juice are not limited only to

					inhibition of CYP3A4, but also involve transport mediated uptake and efflux absorption processes, namely OATP and P-gp. Given the potential importance of these transport processes as discussed in the 'Note for Guidance on Drug Interactions', the information that desloratadine has a low potential for interactions at the absorption site was added to section 4.5 of the SPC.
II/0001	Extension of indication to include Chronic Idiopathic Urticaria Extension of Indication	25/04/2001	06/08/2001	SmPC and PL	For the indication CIU a total of 416 subjects were randomised and 211 received 5 mg desloratadine. The symptoms studied were pruritus, number and size of hives, total symptom score (sum of pruritus, number and size of hives), interference with sleep and daily activities, overall condition and therapeutic response. The primary parameter in both CIU studies was change from baseline in the average reflective pruritus score (reflecting the preceding 12 hours). The two studies showed that Azomyr was effective in reducing symptoms of chronic idiopathic urticaria as compared to placebo. The most common adverse events observed during treatment were headache, dry mouth and fatigue. No serious adverse events were reported in the studies. <Click here for more information>